What Lotus Neuro does

Lotus Neuro is a clinical-stage biotechnology company headquartered in Miami, Florida, focused on developing brain-targeted therapeutics for neuro-oncology and neurodegeneration. The company was spun out of Insightec on December 17, 2025, and is led by CEO Arjun (JJ) Desai, formerly Insightec's Chief Strategic Innovation Officer. It is privately held and funded by Nexus NeuroTech Ventures.

The company's core product is a precision, low-frequency focused ultrasound platform designed to temporarily open the blood-brain barrier (BBB) and enable targeted delivery of therapeutics to brain tissue. The platform is built on Insightec's existing ultrasound technology, which has been used to treat over 25,000 patients globally, giving Lotus Neuro a clinically validated device foundation rather than a de novo system. Initial development programs target glioblastoma and diffuse midline gliomas (neuro-oncology) as well as broader neurodegeneration indications, addressing the widely cited problem that approximately 98% of drugs cannot cross the BBB.

Lotus Neuro is currently in preclinical and early clinical development and has not yet generated commercial revenue. Its revenue model is not publicly disclosed; pricing is not available; and distribution is expected to flow through specialized clinical settings and hospital partnerships capable of administering focused ultrasound treatments once therapies are approved. Today the company's primary counterparties are its parent-collaborator Insightec (which retains device commercialization) and its sole disclosed funder, Nexus NeuroTech Ventures. Its go-to-market motion is therefore partnership- and trial-driven rather than commercial-sales-driven.

Name

Lotus Neuro

Legal name

Lotus Neuro

Website

https://lotusneuro.com

Company type

Private

Founded year

2025

Operating status

Operating

Short description

Lotus Neuro is a Miami-based, clinical-stage biotech spun out of Insightec in December 2025 that develops a focused ultrasound platform to open the blood-brain barrier for targeted drug delivery to treat neuro-oncology and neurodegeneration patients.

Ownership category

akta.pro rank

Product category

Neurological Therapeutics

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Neuro-Oncology (HLAKAFAH)

akta.pro secondary industry

Neurology/CNS Gene Therapies (HLAAACAH)

Keywords

• Focused ultrasound therapy
• Blood-brain barrier opening
• Brain drug delivery
• Neuro-oncology therapeutics
• Clinical-stage biotechnology

Headquarters

HQ city

Miami

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Distribution channels1 record

Marketing channels1 record

Core offering

Lotus Neuro develops a precision, low-frequency focused ultrasound platform that temporarily opens the blood-brain barrier to enable targeted delivery of therapeutics to brain tissue. The company is initially advancing programs in neuro-oncology (glioblastoma, diffuse midline gliomas) and neurodegeneration, leveraging Insightec's clinically validated ultrasound technology.

Product overview

Lotus Neuro is a clinical-stage therapeutics company with a single unified product: a focused ultrasound platform for brain drug delivery. The platform uses precision, low-intensity focused ultrasound technology to temporarily open the blood-brain barrier, enabling targeted delivery of therapeutics directly to brain tissue. This technology builds on Insightec's existing ultrasound platform (which has treated over 25,000 patients globally) and is initially focused on neuro-oncology programs including glioblastoma and diffuse midline gliomas, as well as neurodegeneration treatments.

Differentiator

Problem solved

Functional benefit

Products and services

• Focused Ultrasound Brain Therapeutics Platform A precision, low-frequency focused ultrasound platform that temporarily opens the blood-brain barrier to enable targeted delivery of therapeutics to brain tissue for treating neurological conditions including neuro-oncology and neurodegenerative diseases.
• Glioblastoma Treatment Program A therapeutic program targeting glioblastoma, a type of aggressive brain cancer, using focused ultrasound technology to temporarily open the blood-brain barrier and deliver therapeutics directly to brain tumors.
• Diffuse Midline Gliomas Treatment Program A therapeutic program targeting diffuse midline gliomas (DMG), a type of aggressive pediatric brain cancer, using focused ultrasound technology to temporarily open the blood-brain barrier and deliver therapeutics to brain tumors.
• Neurodegeneration Treatment Program A therapeutic program targeting neurodegenerative diseases using focused ultrasound technology to temporarily open the blood-brain barrier and deliver therapeutics to affected brain tissue.

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• InsightecflagshipStrategic or Co-development PartnerInsightec spun out Lotus Neuro and retains its device innovation and commercialization business. The two companies collaborate on platform integration and scientific collaboration, with Lotus Neuro leveraging Insightec's existing ultrasound technology platform that has been used to treat over 25,000 patients globally. Insightec's clinical data and ultrasound expertise underpin Lotus Neuro's therapeutic development.

Scale indicators1 record

Recent moves9 records

Expansion highlights4 records

Emerging players

• SonALAsense: Clinical-stage company developing sonodynamic therapy using ultrasound-activated agents for brain cancer — adjacent to Lotus Neuro's neuro-oncology focus, with overlapping BBB and brain drug delivery themes.
• Diffusion Pharmaceuticals: Clinical-stage company developing therapeutics that aim to enhance drug delivery across the BBB in CNS cancers — adjacent mechanism and indication overlap with Lotus Neuro's neuro-oncology programs.
• Denali Therapeutics: Clinical-stage biotech developing therapeutics for neurodegeneration (Parkinson's, Alzheimer's) — comparable to Lotus Neuro on the neurodegeneration therapeutic vertical even though the delivery mechanism differs.

Direct peers

• NaviFUS Corporation: Taiwan-based developer of transcranial focused ultrasound systems for BBB opening in neuro-oncology and other CNS disorders, making it a direct comparable on device mechanism and indication focus.
• Insightec: The parent company of Lotus Neuro and the originator of the focused ultrasound platform Lotus Neuro is built upon. Insightec retains its device innovation and commercialization business and is the closest direct comparable, operating in the same focused ultrasound technology category.
• Carthera: Clinical-stage company developing the SonoCloud focused ultrasound implant to open the blood-brain barrier for treating brain tumors (glioblastoma) and other CNS conditions — directly competing with Lotus Neuro on the same therapeutic application and mechanism.

Broad incumbents

• Profound Medical: Commercial-stage focused ultrasound therapy company (TULSA-PRO for prostate, Sonalleve for uterine fibroids) with broader thermal-focused ultrasound capabilities that overlap with Lotus Neuro's underlying device technology category.
• EDAP TMS: Established commercial focused ultrasound company (Ablatherm/Focal One for prostate, ultrasound ablation devices) sharing the same therapeutic ultrasound category as Lotus Neuro but operating in non-CNS indications.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lotus Neuro